Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15666220 | 0.85 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLBCNR2MITF | |
| SCHEMBL13267231 | 0.85 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLBCNR2SMN1; SMN2 | |
| SCHEMBL1365401 | 0.85 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLBCNR2MITF | |
| SCHEMBL31104515 | 0.85 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLBCNR2MITF | |
| SCHEMBL13368676 | 0.85 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLBCNR2MITF | |
| SCHEMBL8740243 | 0.82 | ALDH1A1 (0.43) | ALDH1A1LMNAPOLBCNR2RAB9A | |
| SCHEMBL30268685 | 0.82 | RAB9A (0.44) | ALDH1A1LMNAPOLBCNR2RAB9A | |
| SCHEMBL20817952 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNAPOLBCNR2MITF | |
| SCHEMBL28686802 | 0.81 | CNR2 (0.46) | ALDH1A1LMNAPOLBCNR2MITF | |
| SCHEMBL27837785 | 0.80 | CYP4F2 (0.44) | ALDH1A1LMNAPOLBCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624041-B2 | Heterocyclic compound and use thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-4709371-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2026047037-A1 | MICROBIOCIDAL QUINOLINE-AMIDE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2026-03-05 | — | — | WO | disclosed |
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | PLEXXIKON INC. (US) | 2025-12-30 | — | — | US | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025217247-A1 | TETHERED SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2009086041-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| WO-2008115381-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
| US-5623072-A | CONTROLLING WEED; CROP TOLERANCE | MONSANTO COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5616789-A | CHEMICAL INTERMEDIATE FOR 2-PHENYLPYRIDAZINE HERBICIDE | MONSANTO COMPANY (US) | 1997-04-01 | — | — | US | disclosed |
| US-5559080-A | 3-phenoxypyridazines, herbicidal compositions and uses thereof | MONSANTO COMPANY (US) | 1996-09-24 | — | — | US | disclosed |
| US-5536701-A | 3-pyrazolyloxypyridazines, herbicidal compositions and uses thereof | MONSANTO COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | ALDH1A1 2437/4885LMNA 929/4885POLB 1088/4885 |
| US-20260001845-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | MAPK6, MAPK3, MAPK1 | ALDH1A1 2176/4885LMNA 1636/4885POLB 2466/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 2638/4885LMNA 1584/4885POLB 2718/4885 |
| US-12624041-B2 | Heterocyclic compound and use thereof | TRPC1, TRPC5, TRPC3 | ALDH1A1 1028/4885LMNA 2999/4885POLB 3847/4885 |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | ALDH1A1 1711/4885LMNA 3582/4885POLB 1619/4885 |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ADORA1, ADORA2A | ALDH1A1 114/4885LMNA 1484/4885POLB 2540/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | ALDH1A1 649/4885LMNA 715/4885POLB 1701/4885 |
| US-20250288571-A1 | MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | BRAF, MAP3K1, MAP3K5 | ALDH1A1 3364/4885LMNA 2512/4885POLB 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.